MDGH

Rethinking pharmaceutical development: A not-for-profit model to address global health inequities

Moxidectin combination therapies for lymphatic filariasis

Support MDGH

U.S. FDA expands indication for moxidectin to treat river blindness in children as young as foural Health

MDGH submits an Investigational New Drug Application for dovramilast for the treatment of leprosy type 2 reaction

Ghana rolls out moxidectin, a new treatment for river blindness